{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T02:48:10Z","timestamp":1790045290051,"version":"4.0.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000051","name":"National Human Genome Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000051","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpeds.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pediatrics"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.jpeds.2020.07.033","type":"journal-article","created":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T22:24:13Z","timestamp":1594419853000},"page":"274-280.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Cost-Effectiveness of Nusinersen and Universal Newborn Screening for Spinal Muscular Atrophy"],"prefix":"10.1016","volume":"227","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4349-1519","authenticated-orcid":false,"given":"Ali","family":"Jalali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Rothwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Botkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca A.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell J.","family":"Butterfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpeds.2020.07.033_bib1","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","article-title":"Spinal muscular atrophy","volume":"371","author":"Lunn","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jpeds.2020.07.033_bib2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ejhg.2011.134","article-title":"Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens","volume":"20","author":"Sugarman","year":"2012","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.jpeds.2020.07.033_bib3","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1097\/GIM.0b013e318188d069","article-title":"Carrier screening for spinal muscular atrophy","volume":"10","author":"Prior","year":"2008","journal-title":"Genet Med"},{"key":"10.1016\/j.jpeds.2020.07.033_bib4","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.pcl.2015.03.010","article-title":"Spinal muscular atrophies","volume":"62","author":"Darras","year":"2015","journal-title":"Pediatr Clin North Am"},{"key":"10.1016\/j.jpeds.2020.07.033_bib5","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.nmd.2015.04.009","article-title":"209th ENMC International Workshop: outcome measures and clinical trial readiness in spinal muscular atrophy. November 7-9, 2014; Heemskerk, The Netherlands","volume":"25","author":"Finkel","year":"2015","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.jpeds.2020.07.033_bib6","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","article-title":"Observational study of spinal muscular atrophy type I and implications for clinical trials","volume":"83","author":"Finkel","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.jpeds.2020.07.033_bib7","doi-asserted-by":"crossref","first-page":"e548","DOI":"10.1542\/peds.2004-0668","article-title":"Spinal muscular atrophy: survival pattern and functional status","volume":"114","author":"Chung","year":"2004","journal-title":"Pediatrics"},{"key":"10.1016\/j.jpeds.2020.07.033_bib8","series-title":"Newborn screening for spinal muscular atrophy (SMA): phase I update of the evidence review","author":"Kemper","year":"2017"},{"key":"10.1016\/j.jpeds.2020.07.033_bib9","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2020.07.033_bib10","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2020.07.033_bib11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/dmcn.14027","article-title":"Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps","volume":"61","author":"Gidaro","year":"2019","journal-title":"Dev Med Child Neurol"},{"issue":"15 Suppl","key":"10.1016\/j.jpeds.2020.07.033_bib12","doi-asserted-by":"crossref","first-page":"S25.001","DOI":"10.1212\/WNL.92.15_supplement.S25.001","article-title":"Nusinersen in infants who initiate treatment in a presymptomatic stage of spinal muscular atrophy (SMA): interim efficacy and safety results from the Phase 2 Nurture study","volume":"92","author":"De Vivo","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.jpeds.2020.07.033_bib13","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1056\/NEJMe1712106","article-title":"The dilemma of two innovative therapies for spinal muscular atrophy","volume":"377","author":"van der Ploeg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2020.07.033_bib14","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jamainternmed.2018.0869","article-title":"Concerns about the approval of nusinersen sodium by the US Food and Drug Administration","volume":"178","author":"Gerrity","year":"2018","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jpeds.2020.07.033_bib15","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/jamapediatrics.2018.0733","article-title":"Cost-effectiveness of nusinersen for spinal muscular atrophy-reply","volume":"172","author":"Prasad","year":"2018","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.jpeds.2020.07.033_bib16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/jamapediatrics.2017.4360","article-title":"Nusinersen for spinal muscular atrophy: are we paying too much for too little?","volume":"172","author":"Prasad","year":"2018","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.jpeds.2020.07.033_bib17","series-title":"Pharmacoeconomic review report: Nusinersen (Spinraza): Biogen Canada Inc","year":"2018"},{"key":"10.1016\/j.jpeds.2020.07.033_bib19","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jval.2012.08.2208","article-title":"The effects of diabetes, hypertension, asthma, heart disease, and stroke on quality-adjusted life expectancy","volume":"16","author":"Jia","year":"2013","journal-title":"Value Health"},{"key":"10.1016\/j.jpeds.2020.07.033_bib20","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/S0960-8966(02)00140-2","article-title":"Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation","volume":"12","author":"Eagle","year":"2002","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.jpeds.2020.07.033_bib21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/0272989X08322014","article-title":"Labor market productivity costs for caregivers of children with spina bifida: a population-based analysis","volume":"29","author":"Tilford","year":"2009","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jpeds.2020.07.033_bib22","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/ijns3040034","article-title":"Cost and cost-effectiveness assessments of newborn screening for critical congenital heart disease using pulse oximetry: a review","volume":"3","author":"Grosse","year":"2017","journal-title":"Int J Neonatal Screen"},{"key":"10.1016\/j.jpeds.2020.07.033_bib23","doi-asserted-by":"crossref","first-page":"e595","DOI":"10.1542\/peds.2013-0332","article-title":"Cost-effectiveness of routine screening for critical congenital heart disease in US newborns","volume":"132","author":"Peterson","year":"2013","journal-title":"Pediatrics"},{"key":"10.1016\/j.jpeds.2020.07.033_bib24","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1001\/jamapediatrics.2017.4409","article-title":"Ethical challenges confronted when providing nusinersen treatment for spinal muscular atrophy","volume":"172","author":"Burgart","year":"2018","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.jpeds.2020.07.033_bib25","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s13023-017-0724-z","article-title":"Indirect estimation of the prevalence of spinal muscular atrophy type I, II, and III in the United States","volume":"12","author":"Lally","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jpeds.2020.07.033_bib26","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1586\/14737159.4.1.15","article-title":"Spinal muscular atrophy: molecular genetics and diagnostics","volume":"4","author":"Ogino","year":"2004","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.jpeds.2020.07.033_bib27","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/1475-6773.12612","article-title":"Adjusting health expenditures for inflation: a review of measures for health services research in the United States","volume":"53","author":"Dunn","year":"2018","journal-title":"Health Serv Res"},{"key":"10.1016\/j.jpeds.2020.07.033_bib28","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1378\/chest.109.6.1597","article-title":"Economic cost of home-based care for ventilator-assisted individuals: a preliminary report","volume":"109","author":"Sevick","year":"1996","journal-title":"Chest"},{"key":"10.1016\/j.jpeds.2020.07.033_bib29","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1377\/hlthaff.2015.0706","article-title":"The growing difference between public and private payment rates for inpatient hospital care","volume":"34","author":"Selden","year":"2015","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.jpeds.2020.07.033_bib30","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1377\/hlthaff.2012.0332","article-title":"Contrary to cost-shift theory, lower Medicare hospital payment rates for inpatient care lead to lower private payment rates","volume":"32","author":"White","year":"2013","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.jpeds.2020.07.033_bib31","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1377\/hlthaff.2017.0749","article-title":"Public and private payments for physician office visits","volume":"36","author":"Biener","year":"2017","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.jpeds.2020.07.033_bib32","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1475-6773.2004.00248.x","article-title":"The lifetime distribution of health care costs","volume":"39","author":"Alemayehu","year":"2004","journal-title":"Health Serv Res"},{"key":"10.1016\/j.jpeds.2020.07.033_bib33","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1377\/hlthaff.2013.1224","article-title":"US health spending trends by age and gender: selected years 2002-10","volume":"33","author":"Lassman","year":"2014","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.jpeds.2020.07.033_bib34","doi-asserted-by":"crossref","first-page":"641","DOI":"10.2165\/11591570-000000000-00000","article-title":"Challenges in health state valuation in paediatric economic evaluation: are QALYs contraindicated?","volume":"29","author":"Ungar","year":"2011","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jpeds.2020.07.033_bib35","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2165\/00019053-200725090-00001","article-title":"Measuring health preferences for use in cost-utility and cost-benefit analyses of interventions in children: theoretical and methodological considerations","volume":"25","author":"Prosser","year":"2007","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jpeds.2020.07.033_bib36","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s40273-019-00769-6","article-title":"Cost effectiveness of nusinersen in the treatment of patients with infantile-onset and later-onset spinal muscular atrophy in Sweden","volume":"37","author":"Zuluaga-Sanchez","year":"2019","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jpeds.2020.07.033_bib38","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1017\/S0266462307051550","article-title":"Assessing the economic challenges posed by orphan drugs","volume":"23","author":"Drummond","year":"2007","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.jpeds.2020.07.033_bib39","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/j.1651-2227.2012.02705.x","article-title":"The need for worldwide policy and action plans for rare diseases","volume":"101","author":"Forman","year":"2012","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.jpeds.2020.07.033_bib40","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jval.2018.01.008","article-title":"Evaluating and valuing drugs for rare conditions: no easy answers","volume":"21","author":"Ollendorf","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.jpeds.2020.07.033_bib41","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ppul.24203","article-title":"Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy","volume":"54","author":"Al-Zaidy","year":"2019","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jpeds.2020.07.033_bib42","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40273-019-00794-5","article-title":"Advances in methods and novel applications for measuring family spillover effects of illness","volume":"37","author":"Prosser","year":"2019","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jpeds.2020.07.033_bib43","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s40273-019-00782-9","article-title":"Quantifying family spillover effects in economic evaluations: measurement and valuation of informal care time","volume":"37","author":"Grosse","year":"2019","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jpeds.2020.07.033_bib44","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3233\/JND-180325","article-title":"Position statement: sharing of clinical research data in spinal muscular atrophy to accelerate research and improve outcomes for patients","volume":"5","author":"Lochm\u00fcller","year":"2018","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.jpeds.2020.07.033_bib45","doi-asserted-by":"crossref","first-page":"253.e1","DOI":"10.1016\/j.ajog.2010.01.032","article-title":"The cost-effectiveness of prenatal screening for spinal muscular atrophy","volume":"202","author":"Little","year":"2010","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jpeds.2020.07.033_bib46","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1086\/313954","article-title":"Practice guidelines for the management of community-acquired pneumonia in adults","volume":"31","author":"Bartlett","year":"2000","journal-title":"Clin Infect Dis"}],"container-title":["The Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347620308763?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347620308763?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:06:07Z","timestamp":1758359167000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022347620308763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":44,"alternative-id":["S0022347620308763"],"URL":"https:\/\/doi.org\/10.1016\/j.jpeds.2020.07.033","relation":{},"ISSN":["0022-3476"],"issn-type":[{"value":"0022-3476","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Nusinersen and Universal Newborn Screening for Spinal Muscular Atrophy","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pediatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpeds.2020.07.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}